Brilaroxazine News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Brilaroxazine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Brilaroxazine Today - Breaking & Trending Today
In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism. ....
Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment. ....
In an interview with HCPLive, Larry Ereshefsky, PharmD discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia. ....
The pivotal phase III study of brilaroxazine from Reviva Pharmaceuticals Holdings Inc. for adults with schizophrenia hit its primary endpoint and two key secondary endpoints, following positive phase II data in 2021. The serotonin-dopamine signaling modulator, the company’s lead candidate, is a once-daily treatment. ....